News & Updates

Subscribe to News & Updates feed News & Updates
NCBI: db=pubmed; Term=adrenal tumor
Updated: 5 days 14 hours ago

Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.

Fri, 07/25/2014 - 22:33
Related Articles

Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.

Clin Exp Rheumatol. 2014 Mar-Apr;32(2):275-84

Authors: Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, Oterino A, Sedano MJ, Rueda-Gotor J, Pérez-Martín I, González-Vela MC, Berciano J, González-Gay MA, Blanco R

Abstract
Neurologic manifestations are found in 5-15 % of patients with sarcoidosis. This granulomatous disease may affect any part of the peripheral or the central nervous system, being potentially severe and difficult to treat. Corticosteroids are the cornerstone of therapy in sarcoidosis. However, some patients become resistant or experience side effects to corticosteroids. In these patients, second line therapies including immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate, cyclophosphamide and leflunomide have been used. Anti-TNF-α drugs have been proposed as a therapeutic option for those who are refractory to immunosuppressive drugs or initially in cases of severe sarcoidosis. We report on 5 patients with neurosarcoidosis treated with anti-TNF-α drugs in our center. A literature review of patients with neurosarcoidosis treated with anti-TNF-α drugs was conducted. In our series successful response to anti-TNF-α therapy was achieved. However, the high frequency of relapses following anti-TNF-α discontinuation makes necessary a close follow-up of these patients when the biologic agent is stopped.

PMID: 24321604 [PubMed - indexed for MEDLINE]

[Refractory inflammatory bowel disease: surgical challenges].

Fri, 07/25/2014 - 22:33
Related Articles

[Refractory inflammatory bowel disease: surgical challenges].

Chirurg. 2013 Nov;84(11):945-50

Authors: Buhr HJ, Kroesen AJ

Abstract
Surgery for inflammatory bowel disease under immunosuppressant drugs is a widely discussed topic. Because therapeutic concepts have significantly changed, almost no patient is currently without an immunosuppressant or biologic agent prior to surgery. However, the data whether biological agents and immunosuppressant are a risk factor are very inconsistent. Concerning Crohn's disease, monotherapy with immunosuppressants or biological agents seems to have no negative influence on the postoperative results. In contrast, however, for ulcerative colitis more publications recognise biologic agents and immunosuppressants as a single therapy as a risk factor for infections. To reduce the general risk, all risk factors have to be reduced. In Crohn's disease, nutritional status must be optimised, corticoids should be reduced, biological agents and immunosuppressant drugs should be stopped, protection of an eventual anastomosis by a stoma. For ulcerative colitis in high-risk patients, a three-stage restaurative proctocolectomy is favoured to a one- or two-staged proctocolectomy.

PMID: 24170117 [PubMed - indexed for MEDLINE]

Multilocular bronchogenic cyst of the bilateral adrenal: report of a rare case and review of literature.

Fri, 07/18/2014 - 20:40

Multilocular bronchogenic cyst of the bilateral adrenal: report of a rare case and review of literature.

Int J Clin Exp Pathol. 2014;7(6):3418-22

Authors: Cao DH, Zheng S, Lv X, Yin R, Liu LR, Yang L, Huang Y, Wei Q

Abstract
PURPOSE: Bronchogenic cysts are rare benign congenital anomalies, originating from the embryonic foregut ventral segment. Adrenal bronchogenic cyst is a rare form of this anomaly. One extremely rare case of bilateral adrenal multilocular bronchogenic cyst in our hospital was reported and the relevant literatures were reviewed. Significant findings: A 51-year-old man suffered from an intermittent vague headache, fatigue and hypertension history for 2 years, which were gradually worsened in a week. Imaging tests showed bilateral suprarenal mass and left renal cysts. After underwent two retroperitoneal laparoscopic adrenal gland tumor separately, they were all proved to be both the multilocular bronchogenic cyst located in bilateral adrenal gland by histopathological examination.
CONCLUSIONS: This report confirms the bronchogenic cyst that can be involved bilateral joint in the adrenal gland. And we demonstrated retroperitoneoscopic surgical management is effective in the treatment of the disease.

PMID: 25031770 [PubMed - in process]

Paraganglioma of the pancreas: a potentially functional and malignant tumor.

Fri, 07/18/2014 - 20:40

Paraganglioma of the pancreas: a potentially functional and malignant tumor.

World J Surg Oncol. 2014 Jul 17;12(1):218

Authors: Zhang L, Liao Q, Hu Y, Zhao Y

Abstract
Paragangliomas are neoplasms that arise from extra-adrenal chromaffin cells. Pancreatic paragangliomas are rare, and few are malignant. To the best of our knowledge, no cases of functional pancreatic paragangliomas have been reported in the literature to date. We present two cases of pancreatic paragangliomas with pathological confirmation. In the case 1, clinical testing and pathological analysis revealed functional and malignant characteristics of the tumor, which carried a poor prognosis. In case 2, functional paraganglioma was suspected. The clinical presentations and outcomes of these two patients are summarized, and the relevant literature is reviewed. Because of the small number of cases reported previously, few characteristics of these tumors are known. The best methods of predicting the malignant and functional potential of these tumors remain unknown. We propose careful preoperative treatment and close postoperative follow-up of paraganglioma patients because of the functional and malignant potential of these tumors.

PMID: 25030833 [PubMed - as supplied by publisher]

Comparison of laparoscopic and open adrenalectomy.

Fri, 07/18/2014 - 20:40
Related Articles

Comparison of laparoscopic and open adrenalectomy.

Acta Chir Belg. 2013 May-Jun;113(3):203-7

Authors: Bulus H, Uslu HY, Karakoyun R, Koçak S

Abstract
UNLABELLED: Laparoscopic adrenalectomy is one of the most significant advances in the past 20 years for treating adrenal disorders. Laparoscopic adrenalectomy has been the golden standard procedure for all adrenal pathologies since it was first defined in 1992. Laparoscopic adrenalectomy is preferred and has advantages such as less postoperative pain, earlier resumption of oral intake, shorter hospital stay, earlier return to normal life and better esthetical results. In our study we compared morbidity and mortality rates of laparoscopic and open adrenalectomy cases.
MATERIAL AND METHODS: In Ankara University Faculty of Medicine General Surgery department 92 cases of adrenalectomy were performed between january 2000-july 2006. The patients were evaluated for age, sex, duration of perioperative hospital stay, resumption of oral intake, duration of operation, surgical wound infection, conversion rate and complications.
RESULTS: In patients who underwent laparoscopic surgery, rate of conversion to open surgery was 9.3% (4 patients). The mean operative duration in the laparoscopic adrenalectomy group was 150 minutes and the mean operative duration in the open adrenalectomy group was 120 minutes (p = 0.001). Surgical wound infection rate was 6% in the open adrenalectomy group and 2% in the laparoscopic adrenalectomy group. Mean perioperative hospital stay was 7.1 days in the open adrenalectomy group and 5.1 days in the laparoscopic adrenalectomy group. Time to resumption of oral intake was 2.42 days in the open adrenalectomy group and 1.05 days in the laparoscopic adrenalectomy group (p = 0.001). There was no perioperative mortality in none of the groups.
CONCLUSION: Laparoscopic adrenalectomy is the golden standard surgical treatment for benign and selected malignant adrenal diseases. Laparoscopic adrenalectomy is a safe and effective technique and has advantages such as less postoperative pain, earlier resumption to oral intake, shorter hospital stay, earlier return to normal life and better esthetical results compared to open adrenalectomy.

PMID: 24941717 [PubMed - indexed for MEDLINE]

[Chromogranin A and neuroendocrine tumors].

Fri, 07/18/2014 - 20:40
Related Articles

[Chromogranin A and neuroendocrine tumors].

Endocrinol Nutr. 2013 Aug-Sep;60(7):386-95

Authors: Díaz Pérez JÁ, Currás Freixes M

Abstract
Chromogranin A (CgA) is the most abundant granin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As a tumor marker is moderately sensitive and nonspecific. Despite the limitations of testing methods, which require careful interpretation, especially in the case of gastrinomas, patients treated with somatostatin analogues, and poorly differentiated tumors, it is the best tumor marker in GEP-NETs and may be of value in other tumors with neuroendocrine differentiation. CgA may be used as a marker in blood or tissue samples through immunohistochemical techniques. CgA levels correlate with tumor burden and extension and may be used for diagnosis and monitoring of GEP-NETs, especially midgut carcinoids and endocrine pancreatic tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments.

PMID: 23271036 [PubMed - indexed for MEDLINE]

[Adrenocorticotropic-secreting pheochromocytoma].

Fri, 07/18/2014 - 20:40
Related Articles

[Adrenocorticotropic-secreting pheochromocytoma].

Endocrinol Nutr. 2013 Aug-Sep;60(7):418-20

Authors: Martín Jiménez ML, Palacios García N, Salas Antón C, Armengod Grao L, Aller Pardo J

PMID: 23246281 [PubMed - indexed for MEDLINE]

[Familial pheochromocytoma associated to neurofibromatosis type 1].

Fri, 07/18/2014 - 20:40
Related Articles

[Familial pheochromocytoma associated to neurofibromatosis type 1].

Endocrinol Nutr. 2013 Aug-Sep;60(7):421-2

Authors: Ollero García-Agulló D, Iriarte Beroiz A, Rojo Alvaro J, Munárriz P, Forga Llenas L

PMID: 23182535 [PubMed - indexed for MEDLINE]

Expression of steroidogenic factor 1 in canine cortisol-secreting adrenocortical tumors and normal adrenals.

Fri, 07/11/2014 - 18:25
Related Articles

Expression of steroidogenic factor 1 in canine cortisol-secreting adrenocortical tumors and normal adrenals.

Domest Anim Endocrinol. 2014 Apr 28;49C:1-5

Authors: Galac S, Kool MM, van den Berg MF, Mol JA, Kooistra HS

Abstract
We report on a screening for the relative messenger RNA (mRNA) and protein expression of steroidogenic factor 1 (SF-1) in normal canine adrenals (n = 10) and cortisol-secreting adrenocortical tumors (11 adenomas and 26 carcinomas). The relative mRNA expression of SF-1 was determined by quantitative real-time polymerase chain reaction analysis and revealed no differences between normal adrenals, adenomas, and carcinomas. Immunohistochemistry demonstrated SF-1 protein expression in a nuclear pattern throughout the normal adrenal cortex and a predominantly nuclear staining pattern in adrenocortical tumors. Of the 15 dogs available for follow up, 7 dogs developed hypercortisolism within 2.5 yr after adrenalectomy, with metastatic disease in 6 dogs and adrenocortical tumor regrowth in 1 dog. The relative SF-1 mRNA expression in dogs with early recurrence was greater (2.46-fold, P = 0.020) than in dogs in remission for at least 2.5 yr after adrenalectomy. In conclusion, we demonstrated the presence of SF-1 expression in normal canine adrenals and adrenocortical tumors. The high SF-1 mRNA expression in carcinomas with early recurrence might indicate its value as a prognostic marker, as well as its potential for therapeutic development.

PMID: 25010021 [PubMed - as supplied by publisher]

Metastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report.

Fri, 07/11/2014 - 18:25
Related Articles

Metastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report.

Iran J Otorhinolaryngol. 2014 Jul;26(76):185-90

Authors: Abbaszadeh-Bidokhty H, Motallebnejad M, Rajabi-Moghaddam M

Abstract
INTRODUCTION: Metastatic lesions of the oral cavity are extremely rare, accounting for approximately 1% of all malignant oral tumors. The most common primary sources of metastatic tumors in the oral region are, from the most to the least common, the breast, lung, kidney, bone, and colon. Renal cell carcinoma accounts for nearly 3% of all adult malignancies. It usually metastasizes to the lungs, bone, adrenal glands, and regional lymph nodes. The incidence of metastasis from renal cell carcinoma to the head and neck region is very low. The tongue is considered a very rare atypical ear, nose, and throat (ENT) location for metastasis of renal cell carcinoma. The present case from Iran reports tongue metastasis of renal cell carcinoma (RCC).
CASE REPORT: The following report is based on an 80-year old male patient with a tongue lesion and ambiguous past medical history that ultimately leads to diagnosis of a metastatic RCC. We also updated a previous literature review that was published 2008. A histopathological differential diagnosis for clear-cell tumors is also discussed.
CONCLUSION: Because of the rarity of metastatic tumors of the oral region as well as the presence of other lesions with clear cells, diagnosis of metastatic clear-cell RCC in the oral cavity can be very difficult and challenging.

PMID: 25009810 [PubMed]

[Adrenal myelolipoma--report of 15 patients].

Fri, 07/11/2014 - 18:25
Related Articles

[Adrenal myelolipoma--report of 15 patients].

Acta Med Croatica. 2013 Jun;67(3):255-8

Authors: Bezjak M, Sesar P, Ulamec M, Pavić I, Mijić A, Spajić B, Kruslin B

Abstract
Myelolipoma is a rare, benign, non-functioning tumor most frequently located in the adrenal cortex. It consists of mature fatty tissue with components of hematopoietic tissue in different proportions. There are certain ambiguities related to the diagnosis and therapy of myelolipoma, and it is therefore important to keep in view all the aspects of the lesion and the circumstances in which it develops. This paper presents a series of 15 patients with myelolipoma diagnosed at the Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center. Out of 15 patients, 10 were men (one of them with bilateral tumor) aged 41 to 73, and 5 were women aged 51 to 54. Macroscopically, the tumors were oval, encapsulated, yellowish, soft masses located in the adrenal glands. The diameter of the tumors ranged between 0.5 and 13.9 cm. Microscopically, they consisted of multiplied mature adipose cells combined with myeloid tissue composed largely of megakaryocytes, erythroid cells and lymphocytes. In all patients, the postoperative course was uneventful with no recurrences.

PMID: 25007436 [PubMed - in process]

Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.

Fri, 07/11/2014 - 18:25
Related Articles

Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.

J Clin Endocrinol Metab. 2014 May;99(5):1790-7

Authors: Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X

Abstract
CONTEXT: The mechanisms causing excessive aldosterone production and hypertension in primary aldosteronism (PA) are complex and often incompletely recognized. Autoantibodies to the angiotensin AT1 receptor (AT1R) have been reported in some PA patients with an aldosterone-producing adenoma but not with idiopathic adrenal hyperplasia.
OBJECTIVE: We investigated whether these autoantibodies will activate AT1R and thereby potentially contribute to the pathophysiology of PA.
DESIGN: AT1R autoantibody activity in sera and/or IgG purified from 13 biochemically confirmed PA patients was measured using AT1R-transfected cells, and their contractile effects were assayed using perfused rat cremaster arterioles. Aldosterone stimulation was measured in vitro using isolated human adrenal carcinoma (HAC15) adrenal cells. These data were compared with sera obtained from a group of normotensive control subjects who were expected to have negligible AT1R autoantibodies.
RESULTS: Sera from each of the 13 PA patients significantly increased AT1R activation in AT1R-transfected cells compared with 20 control subjects, and this activity was inhibited by the selective AT1R blocker losartan. Sera and IgG purified from AT1R autoantibody-positive sera demonstrated significant vasoconstrictive effects in isolated rat cremaster arterioles and were blocked by losartan. Moreover, the AT1R autoantibody-positive IgG directly stimulated aldosterone production in the cultured adrenal cells and enhanced angiotensin-induced aldosterone production in these cells, and these effects were blocked by candesartan.
CONCLUSIONS: These data support a probable pathophysiological role for AT1R autoantibodies in PA and thereby raise important etiological and therapeutic implications.

PMID: 24552217 [PubMed - indexed for MEDLINE]

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models.

Fri, 07/04/2014 - 16:33
Related Articles

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models.

In Vivo. 2014 07-08;28(4):425-434

Authors: Daudigeos-Dubus E, LE Dret L, Rouffiac V, Bawa O, Leguerney I, Opolon P, Vassal G, Geoerger B

Abstract
Background/Aim: Treatment of metastatic neuroblastoma remains a challenge in pediatric oncology. Relevant preclinical models may improve exploration of oncogenesis and new therapies. We developed new orthotopic and metastatic models derived from stage 4 neuroblastoma. Material and Methods: Orthotopic and systemic models were established in BalbC Rag2(-/-)gammaC(-/-) mice following adrenal and intravenous injection of luciferase-transfected IMR-32 and IGR-N91 cells, respectively. Results: All four models exhibited 100% tumor take rate. Metastatic spread of orthotopic IMR-32-Luc cells was observed mainly to the lung, liver and bone; that of IGR-N91-Luc cells to liver, spleen and adrenals. Interestingly, systemic IMR-32-Luc cells metastasized rather to the lung, liver and bone, and IGR-N91-Luc to liver, lung, spleen and adrenals. Feasibility of non-invasive, real-time antitumor response evaluation was validated in the systemic models. Conclusion: These neuroblastoma models with distinct patterns of metastatic spread represent relevant tools for exploring local and metastatic tumor cell tropism, mechanisms of spread and evaluating new cancer therapeutics.

PMID: 24982206 [PubMed - as supplied by publisher]

Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993.

Fri, 07/04/2014 - 16:33
Related Articles

Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993.

Eur J Cancer. 2013 Jul;49(11):2579-86

Authors: Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll-Franse LV, Haak HR

Abstract
BACKGROUND: The reported annual incidence of adrenocortical carcinoma (ACC) is 0.5-2.0 cases per million individuals. Updated population-based studies on incidence are lacking. The aim of this nationwide survey was to describe the incidence and survival rates of ACC in the Netherlands. Secondary objectives were to evaluate changes in both survival rates and the number of patients undergoing surgery.
METHODS: All ACC patients registered in the Netherlands Cancer Registry (NCR) between 1993 and 2010 were included. Data on demographics, stage of disease, primary treatment modality and survival were evaluated.
RESULTS: Included were 359 patients, 196 of whom were female (55%). Median age at diagnosis was 56 years (range 1-91). The 5-year age-standardised incidence rate decreased from 1.3 to 1.0 per one million person-years. Median survival for patients with stage I-II, stage III and stage IV disease was 159 months (95% confidence interval (CI) 93-225 months), 26 months (95% CI: 4-48 months) and 5 months (95% CI: 2-7 months), respectively (P<0.001). Improvement in survival was not observed, as reflected by the lack of association between survival and time of diagnosis. The percentage of patients receiving treatment within 6 months after diagnosis increased significantly from 76% in 1993-1998 to 88% in 2005-2010 (P=0.047), mainly due to an increase in surgery for stage III-IV patients.
CONCLUSION: These nationwide data provide an up-to-date survey of the epidemiology of ACC in the Netherlands. A trend towards a decreasing overall incidence rate was observed. Survival rates did not change during this period despite an increased number of surgical procedures.

PMID: 23561851 [PubMed - indexed for MEDLINE]

Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma.

Fri, 07/04/2014 - 16:33
Related Articles

Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma.

Endocrine. 2013 Oct;44(2):532-6

Authors: Iacobellis G, Petramala L, Barbaro G, Kargi AY, Serra V, Zinnamosca L, Colangelo L, Marinelli C, Ciardi A, De Toma G, Letizia C

Abstract
Emerging evidences indicate that patients diagnosed with adrenal incidentaloma may present with cardiovascular complications. Epicardial fat is known to play a role in left ventricle (LV) changes. Whether epicardial fat can be associated with LV mass (LVM) in patients with incidentaloma is unknown. We test the hypothesis that echocardiographic epicardial fat thickness is independently related to LVM in a well-studied group of subjects with adrenal incidentaloma. 46 consecutive patients (age 59 ± 9 years) with imaging diagnosis of adrenal incidentaloma and 30 healthy controls underwent echocardiogram for epicardial fat thickness and LVM measurement. Non-functional incidentaloma was confirmed in 40 subjects, whereas 6 patients were actually diagnosed with mild Cushing's syndrome. Epicardial fat thickness was significantly higher in patients with incidentaloma and mild Cushing's syndrome when compared to controls, (p < 0.01 for both). LVM(h2.7) was higher in subjects with adrenal incidentaloma than in controls and higher in subjects with mild Cushing's syndrome than in those with adrenal incidentaloma (p < 0.05 and p < 0.01). Multiple regression analysis showed that epicardial fat thickness was the best correlate (R (2) = 0.36, β 2.8, p < 0.01) of LVM in overall study patients. We showed for the first time that (1) epicardial fat thickness and LVM are higher in subjects with adrenal incidentaloma and (2) epicardial fat thickness independently correlates with LVM. Echocardiographic epicardial fat may serve as non-invasive marker of visceral fat and earlier cardiac abnormalities in patients with adrenal incidentaloma.

PMID: 23430367 [PubMed - indexed for MEDLINE]

Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Fri, 06/27/2014 - 15:47
Related Articles

Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.

Endocr Pathol. 2013 Dec;24(4):199-205

Authors: Castelblanco E, Santacana M, Valls J, de Cubas A, Cascón A, Robledo M, Matias-Guiu X

Abstract
This is a confirmatory study about usefulness of SDHB and SDHA immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Paraganglioma/pheochromocytoma syndrome (PGL/PCC syndrome) consists of different entities, associated with germline mutations in five different genes: SDHD, SDHAF2, SDHC, SDHA and SDHB. It has been suggested that negative immunostaining of SDHB can be taken as an indicator of the presence of a mutation in one of the five SDH genes. We have performed SDHB and SDHA immunohistochemical staining in a series of paragangliomas and pheochromocytomas from 64 patients. The patients had been previously checked for mutations in SDHD, SDHC and SDHB, but also for mutation in RET and VHL. All 14 patients with SDH mutations (9 with SDHB and 5 with SDHD mutations) exhibited negative or weak-diffuse SDHB staining pattern in tumour tissue, whereas cells of the 23 RET mutated and 8 VHL mutated tumours showed a positive SDHB immunostaining. Sixteen of the patients that did not exhibit a mutation in any gene showed positive SDHB immunostaining in tumour tissue, while only three of the patients without mutation exhibited negative staining. All patients exhibited positive pattern of SDHA immunostaining. The results confirm the value of SDHB immunohistochemical status in assessment of germline mutations in PGL/PCC syndrome.

PMID: 24096807 [PubMed - indexed for MEDLINE]

A founder SDHB mutation in Portuguese paraganglioma patients.

Fri, 06/27/2014 - 15:47
Related Articles

A founder SDHB mutation in Portuguese paraganglioma patients.

Endocr Relat Cancer. 2013 Dec;20(6):L23-6

Authors: Martins RG, Nunes JB, Máximo V, Soares P, Peixoto J, Catarino T, Rito T, Soares P, Pereira L, Sobrinho-Simões M, Santos AP, Couto J, Henrique R, Matos-Loureiro J, Dias P, Torres I, Lima J

PMID: 24092654 [PubMed - indexed for MEDLINE]

Novel intra-adrenal secondary lymphoid follicle formation.

Fri, 06/27/2014 - 15:47
Related Articles

Novel intra-adrenal secondary lymphoid follicle formation.

Endocr Pathol. 2013 Dec;24(4):248-9

Authors: Nava VE, Torres-Cabala C

PMID: 24014039 [PubMed - indexed for MEDLINE]

Simultaneous bilateral testicular metastases from renal clear cell carcinoma: A case report and review of the literature.

Fri, 06/20/2014 - 13:38
Related Articles

Simultaneous bilateral testicular metastases from renal clear cell carcinoma: A case report and review of the literature.

Oncol Lett. 2014 Apr;7(4):1273-1275

Authors: Moriyama S, Takeshita H, Adachi A, Arai Y, Higuchi S, Tokairin T, Chiba K, Nakagawa K, Noro A

Abstract
Metastasis from renal cell carcinoma (RCC) to the testis is rare. This case report presented an extremely rare case of simultaneous bilateral testicular metastases from RCC in a 65-year-old man who had experienced indolent scrotal enlargement over a period of several months. Scrotal ultrasonography showed 4.0- and 2.0-cm-sized masses in the left and right testes, respectively. Contrast-enhanced computed tomography identified multiple tumors in the kidneys, the pancreas and the left adrenal gland. Left orchiectomy and pathological examination were performed and indicated testicular metastasis from clear cell RCC. The patient underwent complete surgical resection of all residual lesions. Postoperative follow-up examination without adjuvant therapy identified no recurrence over 11 months. This study also reviewed existing literature and determined that retrograde venous spread from the primary kidney tumor to the testis may be an important pathway for testicular metastasis from RCC. In conclusion, RCC can result in testicular metastases not only unilaterally, but also bilaterally, as was observed in the present case.

PMID: 24944706 [PubMed - as supplied by publisher]

Spontaneous complete regression of multiple metastases of hepatocellular carcinoma: A case report.

Fri, 06/20/2014 - 13:38
Related Articles

Spontaneous complete regression of multiple metastases of hepatocellular carcinoma: A case report.

Oncol Lett. 2014 Apr;7(4):1225-1228

Authors: Lim DH, Park KW, Lee SI

Abstract
Spontaneous regression of cancer is a partial or complete disappearance of malignant tumor without specific treatment. Spontaneous regression of hepatocellular carcinoma (HCC) is a rare condition, and the mechanism underlying it is unclear. This report presents a rare case of spontaneous complete regression of HCC, as revealed by tumor markers and imaging studies. A 64-year-old Korean male patient with hepatitis B virus-associated chronic hepatitis presented with HCC. The patient had undergone right lobectomy of the liver but the cancer recurred with multiple lung and adrenal metastases after 14 months. The patient received palliative cytotoxic chemotherapy. However, there was no clinical benefit and the disease progressed. It was decided to discontinue anticancer therapy and administer only supportive care. After approximately six months, the symptoms disappeared and the HCC had completely regressed. The patient remains alive over five years after recurrence.

PMID: 24944697 [PubMed - as supplied by publisher]

Pages